FDMT earnings
4D Molecular Therapeutics Inc. (FDMT) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- 4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™All three patients with 12 months of follow-up demonstrated improvement in multiple FDA-recommended cardiac endpoints at relatively low dose of 1E13 vg/kgCardiac biopsy demonstrated selective and widespread transgene expression within ~50% of cardiomyocytes Engaging with FDA to lift clinical hold and resume enrollment with updated exclusion criteria and highly effective rituximab/sirolimus immunosuppressive regimen to reduce risk of atypical hemolytic uremic syndrome ("aHUS")Otherwise, generally well-tolerated with no liver, heart, or dorsal root ganglia ("DRG") toxicity observedCompany to host live webcast today at 4:30 p.m. EST EMERYVILLE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 4D Mo
- 4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)Cohort 1 patients (n=5) received a single intravitreal injection of 4D-150 (3E10 vg/eye); these patients were high need patients who in the 12 months preceding trial enrollment had a mean annualized anti-VEGF injection rate of ~11Following intravitreal 4D-150, Cohort 1 patients' annualized anti-VEGF injection rate was reduced by 96.7%80% of Cohort 1 patients had not received any supplemental aflibercept injections for up to ~10 months after 4D-150 dosingCohort 1 safety and tolerability of 4D-150 demonstrated to date, with no clinically significant intraocular inflammation or hypotony reportedConference call & webcast to be held Monday November 14, 2022 at 8:00 AM E.T. EMERYVILLE, Calif.
- 4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released Monday, November 14, 2022EMERYVILLE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that enrollment has been completed in all 3 cohorts of the Phase 1 Dose Exploration stage of the Phase 1/2 clinical trial of intravitreal 4D-150 in patients with wet AMD (n=15 patients total; 5 patients per cohort). All 3 cohorts have been cleared for safety, with no dose-limiting toxicities (DLTs) being reported. 4D Molecular Therapeutics also announced that interim clinical data from cohort 1 of this Phase 1/2 clinical trial will be released at 7:30 am E.T., on
- 4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022Cohort 1 lung bronchoscopy sample results demonstrate widespread delivery and expression of the 4D-710 CFTR∆R transgene in 100% of samples from all three patients Cohort 1 safety and tolerability of 4D-710 demonstrated to date, with no drug-related adverse events following aerosol deliveryCohort 1 enrollment completed; Cohort 2 enrollment on-goingConference call & webcast to be held today at 1:30 p.m. PT EMERYVILLE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that interim clinical data from the Phase 1/2 clinica
- 4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022EMERYVILLE, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that interim clinical data from the Phase 1/2 clinical trial of 4D-710 will be presented during a symposium at the upcoming North American Cystic Fibrosis Conference (NACFC), being held November 3-5, 2022. The presentation will include a summary of 4D-710 safety, tolerability, delivery and CFTR transgene expression in patients with cystic fibrosis who have been enrolled on cohort 1 of the dose exploration portion of the clinical trial (n=3; 1E15 vg). NACFC Oral Pres
- 4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease and Provides Clinical Data Update from the 4D-110 Phase 1/2 Clinical Trial in Patients with Choroideremia- First-ever clinical activity data reported on 4D-310 Fabry disease product candidate utilizing the proprietary C102 targeted and evolved vector invented through Therapeutic Vector Evolution - AGA enzyme activity was within, or significantly above, the normal range in all three patients (up to 25-fold mean normal AGA activity) - 4D-310 had a manageable safety profile and no dose-limiting toxicities - 4D-110 was generally well-tolerated, with initial evidence of clinical activity observed - 4DMT to host conference call and webcast on Monday, October 25, 2021 at 2:00 p.m PDT EMERYVILLE, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT), a clini
- 4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Clinical Trial in Patients with Advanced X-linked Retinitis Pigmentosa at the ASRS Annual Meeting4D-125 was well tolerated in all patients treated to-date (n=8), with no dose-limiting toxicities, no serious adverse events and no chronic inflammationClinical activity observed through anatomical measurements of reduced photoreceptor loss in treated vs untreated control eyes on ellipsoid zone area endpointsClinical activity observed through functional improvements in treated vs untreated control eyes on two microperimetry endpoints: (1) mean retinal sensitivity and (2) number of loci with >7 dB improvement4DMT plans to continue enrollment at the 1E12 vg/eye in the dose expansion cohort, including in less advanced patients4DMT to host conference call and webcast on Monday, October 11, 2021
- 4D Molecular Therapeutics Reports Financial Results for the Second Quarter of 2021 and Provides Operational HighlightsEMERYVILLE, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the second quarter of 2021, and provided operational highlights. "Harnessing the power of directed evolution to develop targeted gene therapies is central to 4DMT, and this past quarter we continued to make substantial progress towards our goal," said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. "Importantly, we initiated the expansion of our cGMP manufacturing facilities to support commercial-scale production of our clinical product
- 4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational HighlightsEMERYVILLE, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the first quarter of 2021, and provided operational highlights. "We continue to relentlessly execute and innovate as demonstrated by achievements in our first full quarter as a public company," said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. "The company remains on track to announce initial clinical data from both our 4D-310 Fabry disease product candidate and our 4D-125 XLRP product candidate in the second half of this year. In addit